| Indicators | Browse All

Grifols, S.A. (GRFS)

Healthcare | Drug Manufacturers - General | Barcelona, Spain | NasdaqGS
7.20 USD -0.07 (-0.963%) ⇩ (July 13, 2026, 4 p.m. EDT)

Short-term:★★⯪☆☆Long-term:★★⯪☆☆Dividends:★★★☆☆
Hot Take | July 11, 2026, 4:59 a.m. EDT

The investment case for Grifols remains conflicted, caught between a deteriorating operational reality and a potentially attractive valuation floor. Fundamentally, the company is struggling; revenue is contracting at nearly 5%, and the multi-year price trajectory reflects a brutal 43% decline over the last nine years, suggesting the market has deeply questioned the sustainability of its plasma business. While the latest year saw a modest rebound, the underlying fundamentals—specifically the heavy debt load relative to equity and shrinking top-line growth—do not yet support a high-conviction long-term buy. However, the stock appears mispriced relative to its specific biopharma catalysts, such as the growth in Gamunex and Yimmugo, which analysts believe could drive significant upside. This divergence creates a compelling setup for income investors: the 3.85% dividend yield is robust and well-covered by a low payout ratio, offering a cushion against further volatility. For traders, the options market is screaming caution, with heavy put writing and buying signaling that speculators expect further weakness before any recovery can take hold.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.091425
AutoETS0.093884
AutoARIMA0.093885
MSTL0.100379
MSTL_1260.136101

Forecast horizon: 60 days | Selected: AutoTheta

Forecast Reliability
Score 36%
H-stat 9.23
Ljung-Box p 0.000
Jarque-Bera p 0.251
Excess Kurtosis -0.95
Attribute Value
Sector Healthcare
Ex Dividend Date 2026-07-01
Last Dividend Date 2026-07-01
Debt to Equity Ratio 123.219
Revenue per Share 5.4645
Market Cap 4,900,171,264
Trailing P/E 10.43
Forward P/E 4.98
Beta 1.18
Profit Margins 5.58%
Website https://www.grifols.com

As of July 11, 2026, 4:59 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in out-of-the-money puts (strikes 6.0 and 6.5) across multiple expirations, particularly for August and December. Call activity is sparse and concentrated near the money, while put volume significantly outweighs call volume, indicating a bearish sentiment and a 'buy the dip' strategy rather than a momentum breakout expectation.


Dividend Data

Yield Summary
Last Yield 1yr Yield 3yr Avg 5yr Avg
1.31% 2.94% 0.98% 0.59%
Dividend History
Date Dividend Yield %
2026-07-02 0.0940 1.312849
2025-08-12 0.1730 1.632075
2021-06-03 0.4560 2.720764
2020-10-30 0.2010 1.183746
2019-12-02 0.2200 0.971302
2019-06-07 0.1740 0.915308
2018-11-30 0.2280 1.156187
2018-06-01 0.2510 1.142987
2017-12-01 0.2120 0.954955
2017-05-30 0.1630 0.771415
2016-12-05 0.1910 1.294915
2016-06-02 0.1590 0.944181
2015-12-10 0.1850 1.121212
2015-06-08 0.1675 1.098361
2014-12-04 0.1565 0.904886
2014-06-05 0.1435 0.672289
2013-06-05 0.1295 0.966418
2013-05-29 0.0065 0.048148
Additional Data
dividendRate 0.28
dividendYield 3.91
exDividendDate 2026-07-02
trailingAnnualDividendRate 0.0
trailingAnnualDividendYield 0.0
lastDividendValue 0.094
lastDividendDate 2026-07-02
dividendDate 2026-07-09

Info Dump

Attribute Value
52 Week Change -0.2520576
Address1 Parque Empresarial Can Sant Joan
Address2 Avinguda de la Generalitat, 152-158 Sant Cugat del Valles
All Time High 25.73
All Time Low 4.542857
Ask 8.18
Ask Size 1
Average Daily Volume10 Day 812,630
Average Daily Volume3 Month 692,055
Average Volume 692,055
Average Volume10Days 812,630
Beta 1.178
Bid 6.09
Bid Size 1
Book Value 4.579019
City Barcelona
Compensation As Of Epoch Date 1,767,139,200
Country Spain
Crypto Tradeable 0
Currency USD
Current Price 7.2
Current Ratio 2.474
Custom Price Alert Confidence HIGH
Date Short Interest 1,782,777,600
Day High 7.22
Day Low 7.1
Debt To Equity 123.219
Dividend Date 1,783,555,200
Dividend Rate 0.28
Dividend Yield 3.91
Earnings Call Timestamp End 1,785,268,800
Earnings Call Timestamp Start 1,785,268,800
Earnings Quarterly Growth 0.222
Earnings Timestamp 1,785,268,800
Earnings Timestamp End 1,785,268,800
Earnings Timestamp Start 1,785,268,800
Ebitda 1,676,231,040
Ebitda Margins 0.22535999
Enterprise To Ebitda 12.621
Enterprise To Revenue 2.844
Enterprise Value 21,156,284,416
Eps Current Year 1.06184
Eps Forward 1.4444
Eps Trailing Twelve Months 0.69
Esg Populated 0
Ex Dividend Date 1,782,950,400
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 34 938 00 80 00
Fifty Day Average 7.6488
Fifty Day Average Change -0.4488001
Fifty Day Average Change Percent -0.05867588
Fifty Two Week Change Percent -25.205761
Fifty Two Week High 11.14
Fifty Two Week High Change -3.9400005
Fifty Two Week High Change Percent -0.35368046
Fifty Two Week Low 6.96
Fifty Two Week Low Change 0.23999977
Fifty Two Week Low Change Percent 0.034482725
Fifty Two Week Range 6.96 - 11.14
Financial Currency EUR
First Trade Date Milliseconds 1,307,021,400,000
Five Year Avg Dividend Yield 2.4
Float Shares 837,706,540
Forward Eps 1.4444
Forward P E 4.984769
Free Cashflow 887,539,392
Full Exchange Name NasdaqGS
Full Time Employees 25,000
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.38361
Gross Profits 2,853,323,008
Has Pre Post Market Data 1
Held Percent Insiders 0.0
Held Percent Institutions 0.58233
Implied Shares Outstanding 680,579,407
Industry Drug Manufacturers - General
Industry Disp Drug Manufacturers - General
Industry Key drug-manufacturers-general
Is Earnings Date Estimate 0
Language en-US
Last Dividend Date 1,782,950,400
Last Dividend Value 0.094
Last Fiscal Year End 1,767,139,200
Last Split Date 1,451,865,600
Last Split Factor 2:1
Long Business Summary Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.
Long Name Grifols, S.A.
Market us_market
Market Cap 4,900,171,264
Market State PRE
Max Age 86,400
Message Board Id finmb_734865
Most Recent Quarter 1,774,915,200
Net Income To Common 415,000,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 6,144,014,750
Number Of Analyst Opinions 2
Open 7.16
Operating Cashflow 1,021,000,000
Operating Margins 0.16471
Payout Ratio 0.24700001
Peg Ratio 0.19
Phone 34 935 71 22 00
Previous Close 7.27
Price Eps Current Year 6.780682
Price Hint 2
Price To Book 1.5723891
Price To Sales Trailing12 Months 0.6588023
Profit Margins 0.05579
Quick Ratio 0.782
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.0700002
Regular Market Change Percent -0.962863
Regular Market Day High 7.22
Regular Market Day Low 7.1
Regular Market Day Range 7.1 - 7.22
Regular Market Open 7.16
Regular Market Previous Close 7.27
Regular Market Price 7.2
Regular Market Time 1,783,972,800
Regular Market Volume 542,653
Return On Assets 0.04208
Return On Equity 0.061329998
Revenue Growth -0.048
Revenue Per Share 5.4645
Sand P52 Week Change 0.20847368
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 258,223,442
Shares Percent Shares Out 0.009
Shares Short 6,007,590
Shares Short Previous Month Date 1,780,012,800
Shares Short Prior Month 5,890,416
Short Name Grifols, S.A.
Short Ratio 9.55
Source Interval 15
Symbol GRFS
Target High Price 11.73
Target Low Price 10.0
Target Mean Price 10.865
Target Median Price 10.865
Total Cash 702,000,000
Total Cash Per Share 0.516
Total Debt 9,669,000,192
Total Revenue 7,438,000,128
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps 0.69
Trailing P E 10.434782
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 8.59605
Two Hundred Day Average Change -1.3960505
Two Hundred Day Average Change Percent -0.16240604
Type Disp Equity
Volume 542,653
Website https://www.grifols.com
Zip 8,174